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Prostate cancer has a predilection to metastasise to the bone marrow stroma (BMS) by an as yet uncharacterised mechanism. We
have defined a series of coculture models of invasion, which simulate the blood/BMS boundary and allow the elucidation of the
signalling and mechanics of trans-endothelial migration within the complex bone marrow environment. Confocal microscopy shows
that prostate epithelial cells bind specifically to bone marrow endothelial-to-endothelial cell junctions and initiate endothelial cell
retraction. Trans-endothelial migration proceeds via an epithelial cell pseudopodial process, with complete epithelial migration
occurring after 232743min. Stromal-derived factor-1 (SDF-1)/CXCR4 signalling induced PC-3 to invade across a basement
membrane although the level of invasion was 3.5-fold less than invasion towards BMS (P¼0.0007) or bone marrow endothelial cells
(P¼0.004). Maximal SDF-1 signalling of invasion was completely inhibited by 10mM of the SDF-1 inhibitor T140. However, 10mM
T140 only reduced invasion towards BMS and bone marrow endothelial cells by 59% (P¼0.001) and 29% (P¼0.011), respectively.
This study highlights the need to examine the potential roles of signalling molecules and/or inhibitors, not just in single-cell models but
in coculture models that mimic the complex environment of the bone marrow.
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Prostate cancer (CaP) is a widely prevalent disease (Thompson
et al, 2004) but not all men go on to develop metastases. To do this,
it is essential for tumour cells to migrate within the blood and
lymphatic system. This is known to occur in other cancers
(Taubert et al, 2004) and in many men with malignancy in the
prostate and in other genito-urinary cancers (McIntyre et al, 2000;
Meye et al, 2002). However, the presence of circulating cells per se
does not necessarily lead to metastasis formation (Hood and
Cheresh, 2002). The reasons for this are unclear at the present
time. There is an urgent imperative to gain a better understanding
of this process for two simple reasons. Firstly, men who develop
bone metastases from CaP will almost invariably die from their
disease in the absence of an intercurrent illness. Secondly, there
are large numbers of men with a diagnosis of CaP whose disease
will remain localised for long periods of time but who are currently
being treated aggressively, with inevitable and perhaps unneces-
sary comorbidity.
The mechanism of metastasis is a complex multistage process
that is only beginning to be understood. Initial steps include the
loss of cell-to-cell adhesion within the tumour by downregulation
of molecular binding complexes such as the E-cadherin/b-catenin
complex (Umbas et al, 1997; Bryden et al, 2002) and intravasation
of tumour cells through the basement membrane by production of
enzymes such as matrix metalloproteinases (Hart et al, 2002). Once
in the peripheral blood, the circulating tumour cell has to bind at
its preferred metastatic site and invade through the local
endothelial barrier to gain access to the underlying stroma (Scott
et al, 2001) where it can then become established (Lang et al, 1997,
1998). We have shown previously that prostate epithelial cells
preferentially bind to bone marrow endothelial cells in an integrin
b1-dependent manner, and that only malignant prostate epithelial
cells invade in response to bone marrow endothelial cells (Scott
et al, 2001). However, the specific mechanisms of invasion through
the bone marrow endothelial barrier and the stimuli for that
invasion are as yet undefined. There is therefore a need for better
understanding of this process using in vitro models, to allow the
identification of the stages and individual components under-
pinning the metastatic process. Such in vitro models would also
provide invaluable preclinical tools for the evaluation of new
anticancer therapies.
Recent studies have shown that many epithelial cancers
metastasise preferentially to the bony skeleton. These include
cancers of the prostate (Taichman et al, 2002), kidney (Schrader
et al, 2002), lung (Burger et al, 2003) breast (Muller et al, 2001) and
skin (Robledo et al, 2001; Murakami et al, 2002). Cells from these
tumour types share many of the trafficking characteristics of
haematopoietic stem cells (HSC) (Muller et al, 2001). The homing
of the HSC to the bone marrow during foetal life and after bone
marrow transplantation has been well characterised. The key
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smolecular axis for this homing has been shown to involve the CXC
chemokine stromal-derived factor-1 (SDF-1 or CXCL12) and its
receptor CXCR4 (CD186). This model is supported by the facts that
both bone marrow endothelial cells and osteoblasts express SDF-1
(Aiuti et al, 1997; Hamada et al, 1998; Ponomaryov et al, 2000),
CXCR4 knockouts do not show haematopoietic engraftment of the
bone marrow (Aiuti et al, 1999) and that the level of CXCR4
expression by HSC determines their ability to engraft the bone
marrow (Peled et al, 1999). It has been shown recently that the
CXCR4/CXCL12 axis also plays a crucial role in the targeting of
several solid tumour metastases, including breast (Muller et al,
2001) kidney (Staller et al, 2003), lung (Burger et al, 2003),
pancreas (Koshiba et al, 2000) and CaP (Taichman et al, 2002; Sun
et al, 2003) to the bone marrow. It has been shown in vitro that
CXCR4 and CXCL12 interactions alongside CCR7/CCL21 interac-
tions trigger pseudopodial invasion by malignant breast epithelial
cells by actin polymerisation (Muller et al, 2001).
The CXCR4/CXCL12 axis is therefore a potential target for
therapeutic intervention in malignancies that metastasise specifi-
cally to the bone marrow. Neutralisation of CXCR4 with
monoclonal antibodies in non-Hodgkin’s lymphoma models has
been proven to be effective in preventing pseudopodial formation
and trans-endothelial migration in vitro and to protect against
tumour challenge in vivo, reducing existing tumour growth while
preventing tumour extravasation (Bertolini et al, 2002). In this
study, we have adapted existing bone marrow invasion models to
represent the blood/BMS (BMS) barrier more closely and we have
used these to follow malignant prostate epithelial invasion of the
bone marrow compartment. Using these models, we have also
evaluated the ability of the small peptide inhibitor of CXCR4, T140
(Tamamura et al, 2001) to inhibit prostatic invasion in vitro.
MATERIAL AND METHODS
Materials
All general reagents were purchased from Sigma-Aldridge, Poole,
UK. Tissue culture medium and horse serum was from Invitrogen,
Paisley, UK with the exception of Ham’s F12 media, PAA
Laboratories, Austria and EBM-2 Bullet kit from Cambrex Bio
Science Ltd, Berkshire, UK. Foetal calf serum (FCS) was supplied
by Labtech International Ltd., Uckfield, East Sussex, UK.
Matrigel
s Basement Membrane Matrix and 8mM cell culture
inserts were from Becton Dickinson Labware, NJ, USA and
Worthington trypsin and collagenase type I from Lorne Labora-
tories Ltd, Twyford, UK. T140 anti CXCR4 peptide was a kind gift
from Professor Nobutaka Fujii, Graduate School of Pharmaceutical
Sciences, Kyoto University, Sakyo-ku, Kyoto, Japan.
Antibodies
Mouse anti-human pan cytokeratin was from Sigma-Aldridge,
Poole, UK; rabbit anti-mouse biotinylated antibody from DAKO
Ltd,. Cambridge, UK and Vectastain Elite ABC kit from Vector
Laboratories, CA, USA. CXCR4 clone 12G5 pure and PE conjugate
and control IgG2a PE were from BD Biosciences Pharmingen,
Oxford, UK.
Cell lines
The prostate cell lines PC-3 (Kaighn et al, 1979) and PNT2-C2
(Berthon et al, 1995) were cultured in Ham’s F12, 7% FCS and
2m ML -glutamine and in RPMI 1640, 10% FCS and 2mML -
glutamine, respectively. PC3-GFP were cultured as standard PC-3
cells but with the addition of Hygromycin B (0.15mgml
 1)
(Sharrard and Maitland, 2000). Cultures were grown at 371Ci na
humidified atmosphere of 5% CO2 in air.
The bone marrow endothelial cell line (BMEC) (Almeida-Porada
and Ascensao, 1996) was a gift from Dr Gracia Almeida-Porada
(University of Nevada, Reno NV, USA). Bone marrow endothelial
cell lines were cultured in EBM-2 Bullet kit/15% FCS and 2mML -
glutamine (EGM-2). Bone marrow endothelial cell line flasks were
precoated prior to cell culture by incubation at 371C for 1h with
50mgml
 1 of fibronectin in PBS. Cultures were grown at 371Ci na
humidified atmosphere of 5% CO2 in air and used up to passage
20. All cell lines were removed from tissue culture flasks by
treatment with Trypsin–EDTA.
Long-term human bone marrow
Bone marrow stroma was cultured from female human ribs
removed during routine surgery, after informed consent, for
nonmalignant renal disease. Preparation for tissue culture used the
method of Coutinho et al, 1993. Briefly, bone marrow cells were
flushed from the rib, resuspended in long-term culture medium
(Iscove’s modified Dulbecco’s medium, 10% FCS, 10% horse
serum and 5 10
 7 M hydrocortisone) before 2 10
7 cells were
plated into 25cm
2 tissue culture flasks. The cultures were grown at
331Ci n5 %C O 2 in air for 4–5 weeks until haemopoietically active
areas were observed. All cells were removed from tissue culture
flasks by treatment with trypsin–EDTA.
Primary prostate epithelial cell cultures
With informed consent prostatic tissue was obtained from male
subjects undergoing trans-urethral resection for bladder outflow
obstruction arising from CaP or benign prostatic hyperplasia
(BPH). Each individual prostate chip was bisected for histological
diagnostic evaluation and for tissue culture. Prostate epithelial
cells and fibroblasts were isolated by collagenase digestion
followed by differential centrifugation (Lang et al, 1998). Epithelial
cells were grown in flasks in keratinocyte-SFM at 371Ci na
humidified atmosphere of 5% CO2 in air and then used at passage
1–3. All cells were removed from tissue culture flasks by treatment
with trypsin–EDTA.
Measurement of invasion through BMEC using confocal
microscopy
This was carried out using time lapse confocal microscopy
measurements. Bone marrow endothelial cell line cells were grown
on autoclaved glass coverslips (40mm) precoated with fibronectin
(50mgml
 1) until confluent. The coverslip was then washed and
mounted in a Bioptechs FC2 heated chamber closed to the external
environment containing EGM-2 media. In all, 5 10
5 PC3-GFP
cells in EGM-2 were added and allowed to bind for 1h, after which
any unbound cells were removed and fresh EGM-2 added. The
Bioptechs FC2 closed chamber system with both chamber and
objective temperature control was then mounted onto a Zeiss
LSM510 based around an AxioVert 100 M. An argon 25mW
(Coherent) laser was employed for GFP excitation (458nm
excitation, 505nm long-pass filter, laser power 3% transmittance)
and simultaneous brightfield phase microscopy. Employing a  63
Plan-Apochromat 1.4 NA oil/phase objective lens, images were
captured at a resolution of 512 512 pixels with a pixel dwell time
of 1.76ms. The detector pinhole was set to one airy unit with a stage
motor resolution of 1mM. Visualisation of the data sets was carried
out from coverslip to top of the BMEC layer every 30min over 10h.
Scoring of data was performed using the Zeiss LSM Image
browser viewing time vs three-dimensional (3D) axis. A GFP-
positive cell was scored as to its position in relation to the BMEC
cell layer (Table 1). A ‘þ’ score was recorded if a cell made contact
with the glass coverslip.
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sCellular invasion assay
Migration of seeded epithelial cells across Matrigel and endothelial
cell barriers was measured objectively in invasion chambers. Cell
culture inserts (8mm pore size), coated with Matrigel diluted 1:25
with Dulbecco’s modified Eagle’s media (DMEM), were placed in a
24-well plate containing 1ml of DMEM/0.1% bovine serum
albumin (BSA) with either tissue culture plastic (TCP), BMS or
BMEC at the base. PC-3, PNT2-C2, CaP or BPH epithelial cells
(1 10
5 cells in 0.25ml of DMEM/0.1% BSA) were seeded on to the
top of the inserts. T140 (10mM made up in distilled water) was
added to the media containing PC-3 cells 30min prior to plating in
the assay. The cells were then incubated at 371C for 18h. The
inserts were removed, washed in PBS and the noninvading cells
together with the Matrigel removed from the insert by wiping with
a cotton bud. Inserts were then fixed and stained in 2% crystal
violet/20% methanol and air-dried. Cells on the bottom of the
insert were counted according to the manufacturer’s instructions.
Each experiment was carried out in duplicate.
An endothelial barrier was formed by confluent BMEC cells
cultured on top of Matrigel within the insert. For this, assay inserts
were fixed in methanol/acetone (1:1) prior to staining with mouse
anti-human pan cytokeratin (1:200) followed by biotinylated
rabbit anti-mouse secondary antibody (1:400). This was then
visualised by incubation with streptavidin–HRP complex and DAB
substrate prior to counter staining with haematoxylin.
Immunohistochemistry
Prostate chips were obtained from consenting male subjects
undergoing surgery for bladder outflow obstruction from malig-
nant (CaP) or nonmalignant BPH. The tissue was fixed in formalin,
paraffin embedded and sectioned. Prostatic bone marrow metas-
tases from 8mm trephine core iliac crest biopsies taken with
informed consent from men undergoing subcapsular orchidect-
omy for untreated CaP were sectioned and undecalcified. The
paraffin-embedded sections were first dewaxed followed by citrate
antigen retrieval. Samples were stained with IgG, anti-pan
cytokeratin (1:200) and CXCR4 (5mgml
 1) according to protocols
given above.
Flow cytometry/CXCR4 analysis
The cell lines PC-3, PNT2-C2 and epithelial cells from patients
with CaP or BPH (cultured as described above and used at
passage 1) were fixed with 4% formaldehyde/PBS and labelled
with CXCR4 PE conjugate in PBS. Cells were analysed using a
FACScan flow cytometer (Becton Dickinson). PE was excited at
488nm and the emission was detected at 565715nm band pass.
At least 50000 events were analysed to achieve a signifi-
cant population for analysis. Analysis of results was performed
using WinMDI 2.8.
RESULTS
Measurement of PC3-GFP invasion through BMEC
Previously, Scott et al (2001) found that CaP cells bind to BMS and
bone marrow endothelial primary cells (BME) in preference to
TCP, human umbilical vein endothelial cell line (HUVEC) and
prostate fibroblasts. To examine this phenomenon more closely,
with particular reference to binding and invasion, we used the
GFP-transfected PC-3 cell line in conjunction with BMEC using
confocal microscopy. We found that most of the PC3-GFP cells
bound within 60min and further to Scott et al (2001), we found
Table 1 Time taken (min) for PC3-GFP cells to invade through the
BMEC layer and the percentage of test cells that attained this
0  1234 5 
Time (min)
Stage 1 Stage 2 + Stage 5
Mean (n¼38) 90 136 170 232
Std error (7) 1 31 72 04 3
% Cells 100 65 68 29
Key: PC3-GFP cell volume penetrating upper surface of BMECs: 0¼unbound;
1¼bound; 2¼25% volume invaded; 3¼50% volume invaded; 4¼75% volume
invaded; 5¼100% total invasion; +¼any part of the cell makes contact with the
coverslip.
O h 2.5 h 5 h
A
B
(a)
(b) O h 2.5 h 5 h
Figure 1 (A) PC3-GFP cells after 60min in culture with BMEC cells.
Arrows indicate the joints between endothelial cells. (B) (a) Confocal time
lapse of PC3-GFP cells interacting with BMEC monolayer showing
endothelial cell retraction (arrowed) over a 5h time frame. (b)
Corresponding fluorescent confocal time lapse of PC3 GFP cells.
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sthat they had a marked tendency to bind at endothelial junctional
regions (86.2677.12%; P¼0.003). Figure 1A shows three PC3-GFP
cells at their binding sites after 60min in contact with the BMEC.
Each endothelial cell can be distinguished clearly and the arrows
indicate the junctions at areas where each of the PC3-GFP cells
were bound.
These cells were studied using time-lapse confocal microscopy
over a 10h period taking a series of Z slices through the PC3-GFP
and BMEC layer every 30min to obtain a 3D image. Figure 1B
shows BMEC retraction postbinding of the PC3-GFP cell. At 2.5h
postepithelial binding, there is significant endothelium retraction
(indicated by arrows) along two sides of the invading epithelial cell
with almost complete retraction of the surrounding endothelial
cells after 5h. During this period, the epithelial cell remains in
contact with one of the endothelial cells.
Figure 2A shows the raw unprocessed image of PC3-GFP cells
over a period of 7.5h showing one Z-plane image. For an initial
evaluation of the data, a height coded 3D image was generated at
each time point via the LSM510 software. Depending on the
location in the axial dimension, pixels were pseudocoloured to
generate a two-dimensional image map. By analysing multiple Z-
plane images for each time point, the GFP signal could be tracked
and shown as depth (Figure 2B). Blue indicates 25mM (top of
endothelial layer) down to red 0mM (base of endothelial layer/
coverslip). Over time, the interactions of the PC3-GFP cells with
the endothelial layer can be tracked. The bottom cell in this image
can be seen to move from pale blue through to green, at which
point a small pseudopodial process can be seen to extend
downwards to the coverslip (red) and extend outwards along the
bottom while the rest of cell remains green. At 210min,
this body is drawn down (red colour) below the BMEC layer.
Figure 2C shows this cell as a 3D axial projection. The dashed
area represents a visualisation of the volume taken by the
endothelial cells (this excludes representation of endothelial
joints). Figure 2D shows this cell after further processing.
Image analysis was carried out by applying a median filter
3 3 3 to remove noise. The data were then imported into Imaris
(Bitplane AG) where an isosurface was created, a process of 3D
thresholding to remove 5% of the pixel values consequently
removing background features. The cell of interest was then
examined for movement by using the phase data as a reference in
the lateral and axial dimension. This advancement in technology
has allowed a better understanding of the physical process of
invasion of the epithelial cell through the BMEC layer, showing the
changes of cell shape.
Data were collected from seven experiments totalling 38 cells,
which were scored by two independent investigators regarding the
position of each cell over time. Table 1 shows the scoring regime
that was adopted to identify the level of invasion through the
endothelial layer in stages. We found that 80% of the PC3-GFP cells
had bound within 60min and 100% of the cells had bound to the
endothelial layer within 90min. Within 136min, 65% of these cells
had penetrated to a position half way between the upper and lower
surface of the endothelium, while 68% had contact with the
coverslip by 170min. At this point, many of the cells remained
static and did not proceed further. However, 29% of the total
population did achieve complete invasion through the layer after
232743min.
Stimuli of prostate epithelial cells invasion
Previously, we have shown that the PC-3 cells could be stimulated
to invade through the synthetic basement membrane, Matrigel, in
response to stimuli from indirect coculture with both primary
BME and BMS cells. Therefore, we determined the potential of
BMECs and BMS to stimulate PC-3 invasion and determined the
utility of this assay to evaluate the invasive responses of primary
prostate epithelial cells to different stimuli.
The invasion chamber model, shown in Figure 3A, utilises an
8mM pore invasion chamber precoated with Matrigel suspended
above the stimuli of choice. To eliminate any stimulatory effects of
Figure 2 (A) Confocal time-lapse of PC3-GFP cells interacting with the
BMEC cell layer over 30min increments (unprocessed volume). (B) Height
coded 3D image showing the height each cell is positioned at each time
point (red indicates the bottom of the endothelial layer, blue the top). (C)
3D axial projection of the bottom most cell in the previous images, the
dashed line indicates the volume taken by the endothelial layer but does
not account for endothelial junctions. (D) Four-dimensional isosurface
reconstruction of this cell showing changes in cell volume during invasion.
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sdifferent culture medium, all assays were conducted in the
presence of DMEM/0.1% BSA, which did not effect cell viability
during the course of the assay. The number of cells that invaded
through the Matrigel in response to each stimulus is shown in
Figure 3B. The normal prostate epithelial cell line PNT2-C2 was
not stimulated to invade through Matrigel by BMECs or by BMS.
However, both BMECs and BMS induced PC-3 to invade (P¼0.033
and 0.039, respectively as compared to TCP control) to a similar
degree (P¼0.69).
Replacing the prostate epithelial cell lines with primary prostate
epithelial cells showed that both BMECs and BMS induce
malignant prostate epithelial cells to invade (P¼0.0003 and
0.0009, respectively compared to control). Unlike the cell line
model, BMS had a three-fold greater stimulatory effect on
malignant primary prostate epithelial cells than the BMECs
(P¼0.0093). Both BMECs and BMS did not significantly induce
primary epithelial cells isolated from benign prostates to invade
through Matrigel (P¼0.07 and 0.221, respectively).
Prostate epithelial invasion in the modelled bone marrow
environment
To increase the complexity of the invasion model to mirror the
in vivo bone marrow microenvironment more closely, cell culture
inserts (8mm) were coated with Matrigel and BMEC cells were
grown as a monolayer over the top of the formed Matrigel
basement membrane. These inserts were placed in a well of a
24-well plate containing either TCP or BMS (Figure 4A). As
some endothelial cells migrate through to the base of the
insert, we had to be sure that we would be able to distinguish
between the endothelial and epithelial cells. Instead of standard
crystal violet to stain all cells, we selectively stained for epithelial
cells with an anti-pan cytokeratin antibody and counterstained
with haematoxylin.
The presence of an endothelial barrier does not prevent invasion
of PC-3 cells towards BMS (Figure 4B(a)); however, there is a
marked increase in the number of PC-3 cell invading towards TCP
with significantly similar numbers invading towards both TCP and
BMS stimuli (136732 and 10779; P¼0.498). This is also observed
with the malignant primary prostate epithelial cells; however, the
numbers of invasive cells were low (571.9 and 672.2 towards
TCP and BMS, respectively; P¼0.802). Addition of prostate
epithelial cells induced migration of BMECs through Matrigel in
the presence of TCP (100730 for PC-3 and 78735 for PNT2-C2;
P¼0.0117 and 0.065, respectively). The addition of a BMS stimulus
induced an overall increase in BMEC invasion with or without
prostate epithelial cells. Only PNT2-C2 induced significantly more
BMEC invasion than the no prostate epithelial cell control
(355735 vs 162730; P¼0.00751). Primary prostate epithelial
cells had a weaker effect on the BMECs, inducing fewer endothelial
cells to invade towards TCP, with only BPH cells stimulating
significantly more endothelial cells to invade (7378 vs 34711;
P¼0.037) than the no prostate epithelial cells control. Unlike the
prostate epithelial cell line response, both benign and malignant
primary prostate epithelial cells did not induce significantly more
endothelial invasion in the presence of a BMS stimulus than the no
prostate epithelial cells control (P¼0.8233 and 0.2208 for CaP and
BPH, respectively).
Inhibition of CXCR4 signalling by T140
The utility of these invasion models to analyse the role of specific
stimulators and inhibitors of prostate epithelial cells was assessed.
It has been shown that SDF-1, expressed by both BMS and BMECs
(Aiuti et al, 1997), and its receptor CXCR4 play an important role
in targeting not just blood cells but also prostate epithelial cells
towards the BMS (Taichman et al, 2002; Sun et al, 2003).
Therefore, we examined the ability of SDF-1, and its specific
peptide inhibitor T140, to stimulate invasion of prostate epithelial
cells in our models.
Immunohistochemical analysis of prostate sections taken from
patients with benign disease, localised CaP or bone metastases
(Figure 5A) showed that both BPH and localised CaP expressed
high levels of CXCR4 within the nucleus. Prostate bone metastases,
by contrast, express high levels of CXCR4 in both the nucleus and
the cytoplasm. FACs analysis of PC-3 and PNT2-C2 cell lines and
primary benign and malignant prostate epithelial cells (Figure
A
B
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Figure 3 (A) Matrigel invasion chamber model seeded with 1 10
5
prostate epithelial cells. Prostate epithelial cell were fixed and stained in 2%
crystal violet. Typical field of view of stained cells shown. (B) (a) Number of
PC-3 and PNT2-C2 cells that invaded through Matrigel towards either
TCP, BMEC or BMS (n¼3). (b) Number of primary cultured prostate cells
from patients with CaP (n¼7) or BPH (n¼8) that invaded through
Matrigel towards either TCP, BMEC or BMS. (*) Denotes significant
difference; Po0.05. (**) Denotes significant difference to TCP stimulated
PC-3; Po0.05.
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s5B(b)) shows that similar percentages of PC-3, BPH and CaP
epithelial cells express CXCR4 (P40.05) but expression was lower
in PNT2-C2 cells (23% reduction; P¼0.0048 as compared to CaP).
However, there was considerable and significant variation
(Po0.05) in the levels of CXCR4 expression between primary
and cell lines and in relation to their type. PC-3 cells expressed the
highest levels of CXCR4 followed by primary CaP and BPH
prostate epithelial cells (geometric mean fluorescence of
115.8710.7, 7175.8 and 5174.8, respectively). The lowest level
of expression was seen in the transformed normal prostate
epithelial cell line PNT2-C2 with a geometric mean fluorescence
of 2976.7.
The effect of the specific CXCR4 inhibitor, T140 (Tamamura
et al, 2001, 2003), on prostate epithelial cell invasion was then
assessed in the Matrigel invasion model with the PC-3 cell line
(Figure 6). The invasive stimulatory effect of the maximal invasive
dose of SDF-1, 15ngml
 1 (titration data not shown), was
compared to the invasive stimuli from BMECs and primary BMS
with or without 10mgml
 1 T140 (concentration required to inhibit
completely SDF-1 signalling in prostate epithelial cells (titration
data not shown)). Bone marrow endothelial cell lines and BMS
both induced PC-3 invasion across the Matrigel barrier, as did
15ngml
 1 SDF-1, although SDF-1 induced significantly less PC-3
invasion than either the BMECs (141712 vs 490736 P¼0.0007)
or the BMS (141712 vs 503729 P¼0.0004). Addition of 10mM
T140 resulted in a complete block in invasion towards SDF-1
(P¼0.0103). However, unlike SDF-1-induced invasion, T140 only
reduced the levels of PC-3 invasion incompletely (29% towards
BMEC (P¼0.011) and by 59% towards BMS (P¼0.001)).
DISCUSSION
We have previously developed models allowing the study of the
interactions between malignant prostate epithelial cells and
endothelial or BMS layers (Lang et al, 1997, 1998; Scott et al,
2001). We have developed these models to target the blood/BMS
endothelial barrier specifically, thereby allowing the visualisation
not just of the sites of binding but also of the prostate epithelial
invasive process. The development of such models enables the
characterisation and comprehension of the mechanisms of
metastasis in prostate and other cancers to be carried to a greater
depth. Understanding and modelling this process will not only
elucidate new therapeutic targets but also may help to elaborate
their mode of action. In addition, it will help to explore the
potential therapeutic benefit of novel chemotherapeutic agents
such as T140 (Tamamura et al, 2001).
We have shown that prostate epithelial cells bind preferentially
to primary human bone marrow endothelial cells and that only
malignant prostate epithelial cells can invade through a matrigel
basement membrane (Scott et al, 2001). With a view to creating
robust models of epithelial/endothelial interactions, we have
replaced the primary BME cells with the BMEC cell line. This line
displays characteristics indistinguishable from human primary
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Figure 4 (A) Bone marrow endothelium invasion chamber model seeded with 1 10
5 prostate epithelial cells. Prostate epithelial cells fixed in methanol/
acetone, stained for cytokeratin by immunohistochemistry and counterstained with haematoxylin. Typical field of view of stained cells shown. (B) Number of
(a) PC-3 (n¼5), PNT2-C2 (n¼3), (b) CaP (n¼6) and BPH (n¼5) epithelial cells that invaded through Matrigel and an endothelial barrier towards either
TCP or BMS. (*) Denotes significant difference Po0.05. The number of BMEC cells that invaded through the Matrigel either on their own or in the
presence of prostate epithelial cell lines (c) or primary prostate epithelial cells (d) in response to TCP or BMS. (**) Denotes significant difference to the no
epithelial control, Po0.05.
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sBME cultures (Almeida-Porada and Ascensao, 1996). We have also
utilised an GFP-expressing invasive prostate epithelial cell line,
PC3-GFP (Sharrard and Maitland, 2000), to allow visualisation and
measurement of the process of cellular trans-migration by confocal
microscopy.
Our results show that the prostate epithelial cells bind rapidly to
the BMEC cell layer. This process is complete within 90min,
confirming the findings in previous clinical studies whereby
prostate cells released into the circulation during surgery were
removed from the peripheral blood within 2h (McIntyre et al,
2002). Our results show that the location of the binding is very
specific, with all the PC3-GFP cells binding at endothelial cell
junctions. It has been shown that prostate epithelial cells interact
directly with the BME cells, initially via selectins and this
interaction is then stabilised by integrin binding (Orr et al,
2000). These are not the only binding steps, since antibodies to
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Figure 5 (A) Immunohistochemical staining of prostate sections taken from patients with BPH, CaP or bone metastases. These sections were labelled
with IgG1, anti-pan-cytokeratin and anti CXCR4 (clone 12G5) and stained with DAB (brown). These sections were counterstained using haematoxylin
(blue). (B) FACs CXCR4 receptor expression in primary cultured prostate from patients with CaP (n¼6) or BPH (n¼5) and on the PC-3 and PNT2-C2
prostate cell lines (n¼3). (a) Histograms showing expression of CXCR4 by each cell culture as compared to IgG control (shaded histogram). (b) Percentage
of cells expressing the CXCR4 receptor; (*) denotes significant difference to CXCR4 expression in patients with CaP; Po0.05. (c) Level of expression of
CXCR4 by each prostate epithelial population; (*) denotes significant difference to CaP, Po0.05.
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sCD11a, CD18, LFA-1 and CD31 have also been shown to interfere
with the binding process (Lehr and Pienta, 1998).
Once bound, prostate epithelial cells induce endothelial cell
retraction. The precise mechanism of this process, which is an
essential component of cellular trans-migration, is at present
unclear. A major component of the signalling cascade modulating
endothelial permeability is the intracellular level of Ca
2þ (Curry,
1992). Studies by Lewalle et al (1998) demonstrated that the
binding of breast epithelial cells to HUVECs induced a transitory
rise in HUVEC intracellular concentration of Ca
2þ resulting in
endothelial retraction and epithelial migration. This rise in Ca
2þ
levels and retraction of the endothelial layer is entirely dependent
on cell-to-cell contact and inhibiting this rise in intracellular Ca
2þ
concentration inhibited breast epithelial trans-endothelial migra-
tion. The binding of prostate epithelial cells and melanoma cells
also have induced raised intracellular Ca
2þ levels (Pili et al, 1993),
which correlated with increased binding of the epithelial cells.
Previous studies by our group (Montague et al, 2004) have shown
that treatment of BMEC with the bisphosphonate zoledronic acid,
a potent calcium chelating agent and blocker of the mevalonate
transduction pathway, tightens the endothelial-to-endothelial cell
binding in the absence of prostate epithelial cells. It is also a potent
inhibitor of prostate epithelial trans-endothelial migration. How-
ever, the tightening of the endothelial-to-endothelial cell bonding
is not observed with high doses (100mM) of the weaker bispho-
sphonate pamidronate, or with EDTA, both of which are potent
Ca
2þ chelating agents. Therefore, it is unlikely that endothelial
retraction relates to decreased levels of extracellular Ca
2þ,
although the effects on intracellular Ca
2þ levels at the higher
concentrations observed in relation to endothelial binding
experiments are unknown (Montague et al, 2004).
The effect of agents such as zoledronic acid in reducing the
ability of PC-3 cells to invade across endothelial barriers towards
BMS suggest that a major component affecting migration is
inhibition of transduction pathways related to the Rho axis.
Zoledronic acid is an effective inhibitor of the mevalonate
pathway, which is known to be related to the Rho pathway
through Ras linkage (Virtanen et al, 2002). Inhibition of this
pathway affects downstream prenylation of small GTPases such as
Rho, which is known to be involved integrally in cell motility.
Therefore, an early event following integrin b1-binding may be the
induction of a specific pathway or pathways, which relate to Rho.
Whether or not this is a consequence of flux in intracellular
calcium levels within endothelial cells remains to be determined.
The role of integin b1 and the interaction between the prostate
epithelial cell and the endothelial tight cell junction in relation to
induced rises in intracellular Ca
2þ concentrations is certainly
worthy of further study.
Malignant prostate cells migrate across the endothelial barrier
in a manner similar to melanoma cells (Voura et al, 1998). The
prostate epithelial cells bind rapidly to the endothelial junctions,
where they begin to penetrate the endothelial barrier. The prostate
epithelial cells show marked membrane blebbing and lamellipodial
formation on the lower surface of the cell (Figure 1) at the point of
contact between the two cells. The prostate epithelial cell then
generates a pseudopodial extension, which penetrates the en-
dothelial cell layer, the endothelial cells retract and the prostate cell
moves through the endothelial barrier. As with the migration
across endothelia observed in melanoma cells, prostate epithelial
trans-migration is considerably slower than leukocyte trans-
migration, with 29% of cells completing the transit within 4h.
This extravasation time is comparable to that observed for
melanoma cells (Voura et al, 1998), rat ascites hepatoma cells
(Ohigashi et al, 1989) and other tumour cells (Kramer and
Nicolson, 1979). However, it has been shown that over 50% of
monocytes can cross an endothelium within the first hour of
contact (Sandig et al, 1997) without inducing endothelial cell
retraction. This difference may be due to the fact that epithelial
cells are larger than monocytes and therefore require retraction
of the endothelium, thereby resulting in the significantly increased
time of invasion.
Figure 4B shows that the addition of a BMEC barrier does not
inhibit PC-3 invasion but appears to act as a stimulus in the TCP
control. As shown in Figure 3, both BMS and BMECs are powerful
invasion stimuli, possibly inducing maximal invasion within our
assay system. This would explain why we do not observe an
enhanced effect in the combined BMEC BMS assay model. We have
also shown that trans-endothelial migration by prostate epithelial
cells induces the invasion of bone marrow endothelial cells across
the Matrigel basement membrane. The exact nature of this
basement membrane invasion by the bone marrow endothelial
cells is unknown but may be a result of the weakening of the
basement membrane itself due to prostate epithelial proteolytic
secretions, a phenomenon known to occur during prostate
epithelial migration and metastasis (Hart et al, 2002). However,
Figure 4B shows that in the presence of both PNT2-C2 and BPH
there is significant BMEC invasion without epithelial invasion,
which suggests that the overall integrity of the basement
membrane has remained intact. Figure 4B also shows a marked
increase in endothelial cell invasion in the presence of BMS
suggesting that the BMECs may be responding to factors
other than the potential breakdown of the basement membrane
by the prostate epithelial cell, for example, VEGF or other
angiogenic factors.
Taichman et al (2002) showed that prostate epithelial cells bind
to both osteosarcoma cell lines, MG-63 and SaOS-2, and to human
bone marrow endothelial cells. Previously, we have shown that
both benign and malignant primary prostate epithelial cells bind
preferentially to BMS (Lang et al, 1997, 1998) and to BME cells to a
similar degree (Scott et al, 2001) and that prostate epithelial cells
shed intraoperatively into the peripheral blood during trans-
urethral resection of the prostate are undetectable within 2h of the
end of the operation (McIntyre et al, 2002). Since both benign and
malignant prostate epithelial cells express CXCR4 and bind
preferentially to BME cells, a process which is enhanced by
SDF-1 signalling, it is highly likely that prostate epithelial cells
that are released into the circulation, whether benign or mali-
gnant, are rapidly removed from the blood by binding to the
bone marrow endothelium and possibly to endothelial surfaces in
other capillary beds.
The chemokine receptor, CXCR4, and its endogenous ligand
SDF-1 have been shown to be key components in both chemokine-
induced leucocyte trafficking (Aiuti et al, 1997, 1999; Hamada et al,
1998) and the migration of malignant epithelial cells to the BMS
(Koshiba et al, 2000; Muller et al, 2001; Robledo et al, 2001;
Murakami et al, 2002; Schrader et al, 2002; Taichman et al, 2002;
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 1) with or without the CXCR4 receptor blocked with the
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sBurger et al, 2003; Sun et al, 2003). This has led to the hypothesis
that CXCR4 is the key component of metastatic implantation in
bone marrow and that it represents an important therapeutic
target for metastatic bone disease. Blockade of the CXCR4
signalling in malignant breast epithelial cells either by neutralising
antibodies (Muller et al, 2001) or by peptide antagonists such as
T140 (Tamamura et al, 2003) has been shown to inhibit metastasis
in vivo.
Utilising our in vitro assays of metastasis, we sought to
determine the influence of SDF-1 signalling via CXCR4 as a
stimulus for invasion toward BMS. The analysis of CXCR4
expression by metastatic and benign cell lines, primary prostate
epithelial cells and tissue sections of BPH, primary cancer and
bone metastases demonstrate that all prostate epithelial cells
express CXCR4, although the levels and localisation of expression
vary according to the type of disease affecting the cell. Our results
correlate with the observation of Spano et al (2004) that CXCR4-
positive nuclear staining of non-small-cell lung cancer correlates
with a significantly better outcome. Both BPH and localised CaP
sections show strong CXCR4 nuclear staining while the prostate
bone metastases, a poor prognostic indicator, showed strong
CXCR4 nuclear and cytoplasmic staining. Our results also confirm
the observation of Sun et al (2003) that the level of CXCR4
expression increased with increasing malignancy, with the greatest
expression being observed in the aggressively metastatic cell line
PC-3 and in the human bone metastasis sections. This increasing
expression suggests that CXCR4/SDF-1 signalling may be one of
the key signalling pathways for metastatic spread to the bone.
The importance of this pathway was demonstrated by Taichman
et al (2002), utilising a matrigel basement membrane invasion
assay to show that SDF-1 signalling induced both DU145 and
PC3 cells to invade. However, this study only utilised recombi-
nant SDF-1 and anti-CXCR4 antibody inhibitors and therefore
did not determine whether SDF-1/CXCR4 signalling pathway
was the sole chemo-attractant in the spread of prostate epithelial
cells to the bone. Our study confirms that SDF-1 is a potent
stimulus for invasion but the level of that invasion is significantly
less than that seen by using either BMEC cells and/or BMS alone.
This measured phenomenon is reinforced by the observation that
use of a specific CXCR4 antagonist peptide (T140), at a
concentration which blocks prostate epithelial cell invasion in
response to maximum levels of SDF-1 signalling, does not block
invasion towards either BMEC or BMS completely. Thus, it is
confirmed that while the CXCR4/SDF-1 signalling pathway is
important in prostate epithelial metastasis, it is not the only
signalling pathway involved. This study of CXCR4/SDF-1 signal-
ling in CaP metastasis to the bone marrow demonstrates the need
for more integrated models of bone metastasis. The BMS is a
highly complex environment supporting haematopoiesis and as
such produces a wide variety of chemokines, which may attract
metastatic epithelial cells. While basic models may identify
individual ‘key’ components in metastatic disease, it is necessary
to utilise more complex, coculture models to determine the exact
nature of each signalling pathway within the complex bone
marrow environment.
We have shown that it is possible to generate in vitro models
that are able to mimic the highly complex bone metastatic
environment. These models show that epithelial–endothelial
binding occurs rapidly and that trans-endothelial migration is
initiated at the intercellular joints between multiple endothelial
cells. This results in endothelial cell retraction and epithelial
invasion within 4h. We have also shown that while CXCR4/SDF-1
signalling is an important stimulus for epithelial invasion towards
the bone marrow, it is not the only stimulus emanating from the
bone marrow attracting metastatic prostate epithelial cells.
The main advantage of such models over the standard mono
culture/stimuli variations of Bowden invasion chambers are that
they allow the study of proposed components of the metastatic
process and the effect of novel chemotherapeutic agents within the
relevant background of chemokines and growth factors.
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